2 drugs recalled after a major mix: "serious adverse events", warns the FDA
Patients could take the incorrect drug by accident.
When you pick up Your prescription From the pharmacy, you usually have confidence that you have obtained the right medication. Some pills can be different depending on the brand, but in general, the drugs you receive are supposed to treat what they are prescribed. However, the Food and Drug Administration of the United States (FDA) warns that two drugs have now been recalled after a major mixture, which means that you could not have the right prescription in your pharmacy cabinet. Read the rest to find out more about the recall and why the FDA is concerned about "serious undesirable events".
Read this then: Vitamins sold nationally recalled due to health problems, the FDA warns .
Two different drugs are subject to recall.
The Harvard Drug Group, LLC voluntarily calls a large number of Dronabinol, USP, 2.5 mg capsules and a batch of ziprasidone chlorhydrate capsules, 20 mg, for a June 13 Press release of the FDA. The two drugs were sold under the main pharmaceutical brand and sent to wholesalers of the country on April 5.
According to the press release, dronabinol is used to treat "anorexia associated with weight loss in patients with acquired immune syndrome (AIDS)", as well as nausea and vomiting in patients undergoing chemotherapy against the cancer.
Ziprasidone hydrochloride is used to treat mood and mental disorders such as schizophrenia and bipolar disorder, says release.
The labels were mixed.
The recall was initiated after a customer reported that some boxes labeled like ziprasidone hydrochloride actually contained packages of labeled blistering and containing dronabinol. In light of the mixture, the FDA has issued a warning to consumers, noting that the elderly who take other drugs that affect mental function are "in particular at risk of these reactions".
"There is a reasonable probability that patients who wrongly take Dronabinol capsules, USP, 2.5 mg instead of a ziprasidone hydrochloride, 20 mg of capsules, can undergo serious adverse events of 1) in I miss their dose of ziprasidone and 2) taking an unexpected dose of Dronabinol, "the press release reads AE0FCC31AE342FD3A1346EBB1F342FCB
According to the FDA, missing a dose of ziprasidone can exacerbate the underlying health problems resulting in "instability of mental disease with possible consequences of self-harm or damage to others which could cause medical hospitalization or psychiatric ".
Taking a dose of dronabinol can also have effects that affect mental and physical capacities, in particular "worsening symptoms in patients with mental disease disorders and patients limiting patients to complete dangerous activities (For example, driving a motor vehicle, operation machines), "said the FDA.
In relation: For more information, register for our daily newsletter .
Here is how to identify the products recalled.
If you take one of these drugs, you will want to make sure you have received the right prescription. The recalled Dronabinol capsules came in blister packets of 10 out of 10, with a total of 100 doses. Ziprasidone chlorhydrate capsules recalled are driven in packs of 10 blister, with a total of 40 doses. The two drugs have a lot of T04769.
Ziprasidone hydrochloride capsules can be identified by their "opaque and opaque lavender flesh". They also have "Rdy" and "356" printed on each side. Dronabinol capsules are white and are printed "M2".
Consumers must stop using recalled drugs.
According to the press release, the Harvard Drug Group warns the accounts assigned by mail and collects the products recalled. Wholesalers, distributors and retailers were also invited to stop distributing the products.
The FDA asks consumers to stop taking reminded medications, returning them to their place of purchase and calling their doctor. For specific recall questions, you can reach Sedgwick, Inc. by e-mail to [Protected by e-mail] or by phone at 1-888-759-6904 between 8 a.m. and 5 p.m. Eastern standard hour (east) from Monday to Friday.
You should also report adverse reactions to the reports on unfavorable MEDWatch online, by mail or fax events.
